Professional Documents
Culture Documents
Baby Formula Letter
Baby Formula Letter
We write to you about concerns over the nationwide shortage of baby formula and your
failure to meaningfully address this ongoing crisis. Parents are understandably frustrated and
scared by this shortage. In fact, the formula shortage has reached crisis levels in recent weeks.
The share of baby formula “out of stock across the U.S. hit 40 percent on April 24” and a “total of
26 states have out of stock rates of 40 to 50 percent.”1 Notably, CVS, Walgreens, and Target are
among the stores putting limits on how much formula customers can buy at one time.2
Additionally, there is concern over how this may impact parents participating in the Special
Supplemental Nutrition Program for Women, Infants, and Children (WIC), who rely on the
program’s supply of baby formula for their infant’s nutritional needs.
1
Rob Wile, 40 percent of America’s baby formula supplies are out of stock, NBC News (May 9, 2022), available at
https://www.cnbc.com/2022/05/09/40-percent-of-americas-baby-formula-supplies-are-out-of-stock.html
2
Rachel Paula Abrahamson and Elise Sole, Everything you need to know about the baby formula shortage, Today
(Feb. 9, 2022), available at https://www.today.com/parents/parents/everything-need-know-baby-formula-shortage-
rcna15613?icid=canonical_related
3
Business Wire, Datasembly Data Reveals 31% Out-Of-Stock Rate in April 2022 for Baby Formula; Up 11%
Compared to November 2021, (Apr. 13, 2022), available at
https://www.businesswire.com/news/home/20220413005974/en/Datasembly%E2%80%99s-Data-Reveals-31-Out-
of-Stock-Rate-in-April-2022-for-Baby-Formula-Up-11-Compared-to-November-2021
Letter to President Biden and Dr. Califf
Page 2
affected by these conditions.”4 Mr. Reich warns that baby formula “will continue to demonstrate
higher than average out-of-stock levels.”5
Parents across the country are struggling to keep up with this nationwide shortage of baby
formula. This problem worsened in February 2022 when, Abbott Nutrition, a manufacturer of
infant formula, voluntarily recalled formula produced in its Sturgis, Michigan facility following
reports of infant hospitalizations and death. The facility was subsequently shut down pending an
investigation by the FDA and enhanced testing. Since then, a link has not been established
between the formula produced at the facility and the sickened infants.
On April 29, 2022, the FDA announced that it did not object to Abbott Nutrition
releasing specialty and metabolic formulas produced at the Sturgis facility on a case-by-case
basis. Yet, the FDA has still not cleared the facility to resume the vast majority of its infant
formula production. The prolonged shutdown of the Sturgis facility without any public backup
plan by the administration has greatly exacerbated the current shortage.
Baby formula shortages are an urgent problem that must be addressed immediately. This
new problem is compounded by the historic inflation caused by the Biden administration that is
already burdening families. The office of the U.S. Surgeon General states that families typically
spend $1,200 to $1,500 on infant formula in the first year.6
Just yesterday, the FDA announced a number of steps it will take in an attempt to
“improve supply of infant and specialty formula products.”7 However, this announcement comes
far too late, as parents struggle to find formula for their babies. House Republicans call on the
administration to do more to help parents across this country. This issue is a matter of life and
death, and it is time this administration treats it with the appropriate urgency it deserves.
Accordingly, to assist us in our oversight, please provide the following by May 18, 2022:
1. Please explain the meaning of FDA’s April 29, 2022, update, and if FDA expects its
non-objection to help mitigate the supply shortage? If so, how is it expected to
mitigate the shortage? Please explain how long the additional testing is expected to
take and what the timeline is for reopening Abbott’s Sturgis, Michigan facility.
2. With respect to the steps FDA recently announced, please answer the following:
b. When does the agency expect to see a supply increase, particularly in states
experiencing significant shortages?
4
Id.
5
Id.
6
Office of Surgeon General, Breastfeeding: Surgeon General’s Call to Action Fact Sheet, available at
https://www.hhs.gov/surgeongeneral/reports-and-publications/breastfeeding/factsheet/index.html
7
FDA, FDA Takes Important Steps to Improve Supply of Infant and Specialty Formula Products, (May 10, 2022),
available at https://content.govdelivery.com/accounts/USFDA/bulletins/317391e
Letter to President Biden and Dr. Califf
Page 3
c. Please identify what and the number of specific “reviews” and “certificates”
in the regulatory process you are “expediting” to increase supply.
d. Please explain how you will exercise discretion on “minor labeling issues” to
increase supply?
4. How did FDA account for infant formula supply impacts from the recalls?
6. What action is FDA taking related to the resolution of any issues resulting in the
temporary closure of the facility in Sturgis, MI?
8. What data is available regarding whether non-infants who rely on specialty formula
are having any adverse reactions to currently available formula?
9. What formula production facilities are available beyond U.S. borders, and to what
extent have these facilities been impacted by transit bottlenecks due to COVID
lockdowns?
Please also provide a briefing for the Minority staff of the Energy and Commerce
Committee after sending your written response. If you have any questions, please contact the
Minority Committee staff at (202) 225-3641. Thank you for your attention to this request.
Sincerely,